- Home
- MDRR vs THAR Comparison
MDRR vs THAR Comparison
Compare MDRR & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- THAR
- Stock Information
- Founded
- MDRR 2015
- THAR 2017
- Country
- MDRR United States
- THAR United States
- Employees
- MDRR N/A
- THAR N/A
- Industry
- MDRR Real Estate Investment Trusts
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- THAR Health Care
- Exchange
- MDRR Nasdaq
- THAR Nasdaq
- Market Cap
- MDRR 17.1M
- THAR 16.8M
- IPO Year
- MDRR 2018
- THAR 2022
- Fundamental
- Price
- MDRR $13.15
- THAR $3.03
- Analyst Decision
- MDRR
- THAR Strong Buy
- Analyst Count
- MDRR 0
- THAR 1
- Target Price
- MDRR N/A
- THAR $17.00
- AVG Volume (30 Days)
- MDRR 2.0K
- THAR 743.6K
- Earning Date
- MDRR 11-11-2025
- THAR 11-06-2025
- Dividend Yield
- MDRR 2.03%
- THAR N/A
- EPS Growth
- MDRR N/A
- THAR N/A
- EPS
- MDRR N/A
- THAR N/A
- Revenue
- MDRR $9,649,145.00
- THAR N/A
- Revenue This Year
- MDRR N/A
- THAR N/A
- Revenue Next Year
- MDRR N/A
- THAR N/A
- P/E Ratio
- MDRR N/A
- THAR N/A
- Revenue Growth
- MDRR N/A
- THAR N/A
- 52 Week Low
- MDRR $9.55
- THAR $0.95
- 52 Week High
- MDRR $15.00
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- MDRR 50.62
- THAR 49.12
- Support Level
- MDRR $13.05
- THAR $2.90
- Resistance Level
- MDRR $14.00
- THAR $3.18
- Average True Range (ATR)
- MDRR 0.31
- THAR 0.33
- MACD
- MDRR -0.10
- THAR -0.02
- Stochastic Oscillator
- MDRR 11.07
- THAR 36.76
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.